Richter, J. R., Martin, T. G., Vij, R., Cole, C., Atanackovic, D., Zonder, J. A., … San Miguel, J. (2016). Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). In Journal of Clinical Oncology (Vol. 34, pp. 8005–8005). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.8005

Richter, Joshua Ryan, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, et al. “Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).” In Journal of Clinical Oncology, 34:8005–8005. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.8005.

Richter JR, Martin TG, Vij R, Cole C, Atanackovic D, Zonder JA, et al. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 8005–8005.

Richter, Joshua Ryan, et al. “Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 8005–8005. Crossref, doi:10.1200/jco.2016.34.15_suppl.8005.

Richter JR, Martin TG, Vij R, Cole C, Atanackovic D, Zonder JA, Kaufman JL, Mikhael J, Bensinger W, Dimopoulos MA, Zimmerman TM, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Charpentier E, Strickland SA, San Miguel J. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 8005–8005.